MacroGenics Inc (MGNX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$4.40+3.53%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Intact: The reason to own it still holds.
MacroGenics aims to extend cash through 2028 by selling assets. It targets a $20 million milestone from ZYNYZ sales in 2026. Analysts expect earnings to improve in 2026. The stock price has risen nearly 50% in six months.
The company is still losing money and has fragile quality. Revenue is expected to fall about 29% next year. Recent earnings missed estimates and legal issues add risk.
The market expects about 29% revenue decline next year. Our fair value is near $30.69, close to consensus estimates.
Breaks if: Cash runway does not extend through 2028
Breaks if: EPS remains negative in FY26
Breaks if: Revenue decline exceeds -29% next year
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a turnaround opportunity in the healthcare sector. MGNX is currently loss-making but is focusing on extending its cash runway and divesting non-core operations to enhance its drug development capabilities.
The market appears to have priced in a low expectations gap, indicating that MGNX is seen as relatively cheap compared to its peers. However, there is a divergence in valuation, suggesting that investors may not fully recognize the potential upside from recent strategic moves.
Fundamentals are likely to improve as management continues to extend the cash runway and focus on core drug development. Recent financial performance has been neutral, but the company has shown progress in achieving milestone payments and increasing revenue from collaborations.
The thesis hinges on management's ability to maintain guidance and deliver on key milestones. Additionally, sector performance, particularly from larger players like VRTX and REGN, will be crucial in shaping MGNX's trajectory.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports the growth objective for ZYNYZ. Additionally, achieving the $20 million milestone payment for ZYNYZ reinforces this positive outlook. There are no new threats impacting the thesis at this time.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: Milestone payment falls short of $20 million in 2026
In the next 1 to 3 years, MGNX's success will depend on strategic execution and sector momentum. Not investment advice.